State Lung Cancer Screening Coverage Toolkit | American Lung Association

This website uses cookies. By continuing you are agreeing to our privacy policy.

State Lung Cancer Screening Coverage Toolkit

Presented by The American Lung Association and The University of Texas MD Anderson Cancer Center.

Lung cancer is the nation's leading cancer killer of both women and men in the United States, accounting for approximately 24 percent of cancer deaths. Detecting lung cancer in early stages versus late stage is often the difference between life and death. Low-dose computed tomography (LDCT) screening among those at high risk for lung cancer can help detect this disease earlier and has been shown to reduce the lung cancer death rate by up to 20 percent.

The American Lung Association and The University of Texas MD Anderson Cancer Center have partnered to improve coverage for LDCT screenings for individuals at high risk for lung cancer in state Medicaid programs. Below are a number of resources for public health and lung health organizations, state and location coalitions, and healthcare professionals to use in their work on this issue.

Factsheets & Materials

Webinars

Healthcare Provider Resources

MD Anderson Cancer Center Resources:

We want to hear from you

Other Important Links


    Page Last Updated: April 5, 2019

    Sign up for updates

    Stay up to date on the latest news and information on the fight against lung cancer.

    Red button with telephone
    Ask An Expert

    Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

    Get help
    Red button of two hand prints
    We need your generous support

    Make a difference by delivering research, education and advocacy to those impacted by lung disease.

    Button of turquoise LUNG FORCE swirl
    What is LUNG FORCE?

    LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

    Get involved
    Join the fight for healthy lungs and healthy air.
    Donate Now.